6998 — Genor Biopharma Holdings Income Statement
0.000.00%
Last trade - 00:00
HealthcareHighly SpeculativeSmall Cap
- HK$857.97m
- -HK$265.85m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 13 | 10.3 | 0 | 15.9 | 0 |
Cost of Revenue | |||||
Gross Profit | 3.48 | 7.74 | 0 | 14.9 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 534 | 2,913 | 859 | 799 | 711 |
Operating Profit | -521 | -2,903 | -859 | -783 | -711 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -524 | -3,036 | -866 | -732 | -677 |
Provision for Income Taxes | |||||
Net Income After Taxes | -523 | -3,031 | -865 | -730 | -675 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -522 | -3,027 | -865 | -730 | -674 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -522 | -3,027 | -865 | -730 | -674 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.45 | -12.2 | -1.75 | -1.45 | -1.23 |